NASDAQ:DBTX Decibel Therapeutics - DBTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Decibel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.54 +0.29 (+8.92%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.25▼$3.5750-Day Range$1.86▼$3.3452-Week Range$1.61▼$5.78Volume469,966 shsAverage Volume126,307 shsMarket Capitalization$88.39 millionP/E RatioN/ADividend YieldN/APrice Target$11.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Decibel Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside231.9% Upside$11.75 Price TargetShort InterestBearish15.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.11) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector526th out of 1,027 stocksPharmaceutical Preparations Industry254th out of 500 stocks 3.5 Analyst's Opinion Consensus RatingDecibel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.75, Decibel Therapeutics has a forecasted upside of 231.9% from its current price of $3.54.Amount of Analyst CoverageDecibel Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.05% of the float of Decibel Therapeutics has been sold short.Short Interest Ratio / Days to CoverDecibel Therapeutics has a short interest ratio ("days to cover") of 38.7, which indicates bearish sentiment.Change versus previous monthShort interest in Decibel Therapeutics has recently increased by 5.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDecibel Therapeutics does not currently pay a dividend.Dividend GrowthDecibel Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBTX. Previous Next 1.8 News and Social Media Coverage News SentimentDecibel Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.Search InterestOnly 1 people have searched for DBTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Decibel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Decibel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders39.30% of the stock of Decibel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.88% of the stock of Decibel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Decibel Therapeutics are expected to grow in the coming year, from ($2.11) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Decibel Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Decibel Therapeutics is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDecibel Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Decibel Therapeutics (NASDAQ:DBTX) StockDecibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.Read More Receive DBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DBTX Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comBrokers Set Expectations for Decibel Therapeutics, Inc.'s FY2022 Earnings (NASDAQ:DBTX)January 24, 2023 | msn.comDecibel, Regeneron get UK regulator nod to start trial of hearing loss gene therapyFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.January 24, 2023 | finance.yahoo.comDecibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTOJanuary 20, 2023 | finance.yahoo.comWill Decibel Therapeutics (NASDAQ:DBTX) Spend Its Cash Wisely?January 11, 2023 | msn.comWhy Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionNovember 14, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Decibel Therapeutics (DBTX)November 10, 2022 | finanznachrichten.deDecibel Therapeutics, Inc.: Decibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate UpdateFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.November 9, 2022 | finance.yahoo.comDecibel Therapeutics Reports Third Quarter 2022 Financial Results and Corporate UpdateNovember 2, 2022 | finance.yahoo.comDecibel Therapeutics Announces Submission of Clinical Trial Applications for Lead Gene Therapy Candidate DB-OTOOctober 18, 2022 | seekingalpha.comDecibel Therapeutics hears it may be a takeout target after Lilly acquisition of AkouosOctober 17, 2022 | finance.yahoo.comDecibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing LossOctober 14, 2022 | usatoday.comSave $100 on Bose noise-canceling headphones during the Amazon Prime Early Access saleOctober 12, 2022 | finance.yahoo.comDecibel Therapeutics Appoints Kevin F. McLaughlin to its Board of DirectorsSeptember 20, 2022 | finance.yahoo.comDecibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTOAugust 30, 2022 | nasdaq.comWe Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth CarefullyAugust 16, 2022 | seekingalpha.comDecibel Therapeutics (DBTX) Investor Presentation - SlideshowAugust 13, 2022 | finance.yahoo.comHere's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn SituationAugust 10, 2022 | finance.yahoo.comDecibel Therapeutics Reports Second Quarter 2022 Financial Results and Corporate UpdateJuly 1, 2022 | finance.yahoo.comCould The Decibel Therapeutics, Inc. (NASDAQ:DBTX) Ownership Structure Tell Us Something Useful?June 30, 2022 | marketwatch.comDecibel Therapeutics Shares Continue to Rally After Good Study Data >DBTXJune 28, 2022 | marketwatch.comDecibel Therapeutics Shares Rise Premarket on Positive Study Update >DBTXJune 28, 2022 | markets.businessinsider.comDecibel Therapeutics Delivers Solid Interim Data From Cisplatin-Associated Hearing Loss StudyJune 28, 2022 | seekingalpha.comDecibel Therapeutics up 19% following data on hearing loss drug in cancer patientsJune 28, 2022 | finance.yahoo.comDecibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin ChemotherapyJune 3, 2022 | finance.yahoo.comDecibel Therapeutics to Present at the Jefferies Global Healthcare ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DBTX Company Calendar Last Earnings11/09/2022Today2/06/2023Next Earnings (Estimated)3/17/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBTX CUSIPN/A CIK1656536 Webdecibeltx.com Phone617-370-8701FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.75 High Stock Price Forecast$23.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+231.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.13% Return on Assets-36.41% Debt Debt-to-Equity RatioN/A Current Ratio5.40 Quick Ratio5.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.68 per share Price / Book0.62Miscellaneous Outstanding Shares24,970,000Free Float15,154,000Market Cap$88.39 million OptionableNot Optionable Beta0.14 Key ExecutivesDr. Laurence E. Reid Ph.D. (Age 58)Pres, CEO & Director Comp: $801.23kMr. John J. Lee (Age 54)Chief Devel. Officer Comp: $816.11kMr. M. Charles LibermanCo-Founder & Member of Scientific Advisory BoardDr. Gabriel CorfasCo-Founder & Member of Scientific Advisory BoardDr. Ulrich MüllerCo-Founder & Member of Scientific Advisory BoardDr. Albert S. B. Edge (Age 67)Co-Founder & Member of Scientific Advisory Board Mr. James B. Murphy (Age 65)Interim CFO, Principal Financial Officer & Principal Accounting Officer Ms. Elaine CopeVP of OperationsMs. Anna Trask M.A. (Age 64)Exec. VP & Chief People Officer Mr. Joe Burns Ph.D.Sr. VP of DiscoveryMore ExecutivesKey CompetitorsViracta TherapeuticsNASDAQ:VIRXNRx PharmaceuticalsNASDAQ:NRXPEnlivex TherapeuticsNASDAQ:ENLVMainz Biomed B.V.NASDAQ:MYNZOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 100 shares on 2/2/2023Ownership: 0.000%Alphabet Inc.Bought 1,636,258 shares on 11/16/2022Ownership: 6.553%BlackRock Inc.Sold 7,641 shares on 11/15/2022Ownership: 7.556%Citadel Advisors LLCSold 5,200 shares on 11/15/2022Ownership: 0.000%Renaissance Technologies LLCBought 4,700 shares on 11/14/2022Ownership: 0.129%View All Institutional Transactions DBTX Stock - Frequently Asked Questions Should I buy or sell Decibel Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DBTX shares. View DBTX analyst ratings or view top-rated stocks. What is Decibel Therapeutics' stock price forecast for 2023? 4 Wall Street analysts have issued twelve-month price objectives for Decibel Therapeutics' stock. Their DBTX share price forecasts range from $7.00 to $23.00. On average, they expect the company's share price to reach $11.75 in the next twelve months. This suggests a possible upside of 231.9% from the stock's current price. View analysts price targets for DBTX or view top-rated stocks among Wall Street analysts. How have DBTX shares performed in 2023? Decibel Therapeutics' stock was trading at $2.05 on January 1st, 2023. Since then, DBTX shares have increased by 72.7% and is now trading at $3.54. View the best growth stocks for 2023 here. When is Decibel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 17th 2023. View our DBTX earnings forecast. How were Decibel Therapeutics' earnings last quarter? Decibel Therapeutics, Inc. (NASDAQ:DBTX) issued its earnings results on Wednesday, November, 9th. The company reported ($0.64) EPS for the quarter, hitting analysts' consensus estimates of ($0.64). When did Decibel Therapeutics IPO? (DBTX) raised $100 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO. What is Decibel Therapeutics' stock symbol? Decibel Therapeutics trades on the NASDAQ under the ticker symbol "DBTX." Who are Decibel Therapeutics' major shareholders? Decibel Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anna Trask, Casdin Partners Master Fund, L, Laurence Reid and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Decibel Therapeutics? Shares of DBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Decibel Therapeutics' stock price today? One share of DBTX stock can currently be purchased for approximately $3.54. How much money does Decibel Therapeutics make? Decibel Therapeutics (NASDAQ:DBTX) has a market capitalization of $88.39 million. The company earns $-51,820,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis. How can I contact Decibel Therapeutics? Decibel Therapeutics' mailing address is 1325 Boylston Street Suite 500, Boston MA, 02215. The official website for the company is decibeltx.com. The company can be reached via phone at 617-370-8701 or via email at ir@decibeltx.com. This page (NASDAQ:DBTX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.